Stockreport

Sangamo Therapeutics Announces U.S. FDA Alignment on Abbreviated Pathway to Potential Approval and EMA Prime Eligibility for ST-920 in Fabry Disease

Sangamo Therapeutics, Inc.  (SGMO) 
Last sangamo therapeutics, inc. earnings: 2/28 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: investor.sangamo.com
PDF - U.S. Food and Drug Administration (FDA) advises that a single study with up to 25 patients, in combination with confirmatory evidence, may be acceptable pathway to Bio [Read more]